Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses.

Clinical medicine & research - 1 Nov 2011

Burmester James K, Berg Richard L, Glurich Ingrid, Yale Steven H, Schmelzer John R, Caldwell Michael D

Abstract excerpt

OBJECTIVE: Warfarin is an FDA-approved oral anticoagulant for long-term prevention of thromboembolism. Substantial inter-individual variation in dosing requirements and the narrow therapeutic index of this widely-prescribed drug make safe initiation and dose stabilization challenging. Single nucleotide polymorphisms (SNPs) occurring in CYP2C9, VKORC1, and CYP4F2 genes are known to impact dose, and VKORC1 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P450 Family 4

Share to Mixed Function Oxygenases

Share to Open Reading Frames

Share to Thromboembolism

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 21562135
DOI: 10.3121/cmr.2011.951
PMCID: PMC3251364

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses.PMID 21562135Read ↗

CYP4F2 genetic variant alters required warfarin dose.Semantic proximity Read ↗

Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism.Semantic proximity Read ↗

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.Semantic proximity Read ↗

Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.Semantic proximity Read ↗

Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.Semantic proximity Read ↗

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.Semantic proximity Read ↗

Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.Semantic proximity Read ↗

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.Semantic proximity Read ↗

Warfarin PharmacogeneticsSemantic proximity Read ↗

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.